Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: A 5-year follow-up of an investigational study

Medicine (United States)

Volumn 93, Issue 28, 2014, Pages e290-

  Lee, Jong Hoon ^a   Lee, Sea Won ^a   Jang, Hong Seok ^b   Kim, Sung Hwan ^a   Yoon, Sei Chul ^c  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; ASIAN; BLOOD TOXICITY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; CYBERKNIFE; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; MALE; MELENA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROCTITIS; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION INJURY; RADIATION SAFETY; RECTUM DISEASE; RECURRENCE FREE SURVIVAL; SALVAGE THERAPY; SENESCENCE; STEREOTACTIC BODY RADIATION THERAPY; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; URINARY TRACT DISEASE; VERY ELDERLY; ADENOCARCINOMA; CANCER STAGING; DISEASE FREE SURVIVAL; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIOSURGERY; RETROSPECTIVE STUDY; SOUTH KOREA; SURVIVAL RATE; TIME; TREATMENT OUTCOME; TRENDS;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; COMORBIDITY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOSURGERY; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920131005     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000290     Document Type: Article

References (22)

1. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999; 43: 1095-1101.
2. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol). 2007; 19: 289-301.
3. Macias V, Biete A. Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol. 2009; 11: 437-445.
4. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011; 6: 3.
5. Katz AJ, Santoro M, Diblasio F, et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013; 8: 118.
6. Lee YH, Son SH, Yoon SC, Yu M, et al. Stereotactic body radiotherapy for prostate cancer: a preliminary report. Asia Pac J Clin Oncol. 2014; 10: e46-e53.
7. Lloyd-Davies RW, Collins CD, Swan AV. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years? experience (1962-1984). Urology. 1990; 36: 107-111.
8. Rodrigues G. Is intensity-modulated radiotherapy for prostate cancer ready for prime-time? Can J Urol. 2012; 19: 6381-6382.
9. Fowler J, Chappell R, Ritter M. Is a/b for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001; 50: 1021-1031.
10. Halperin EC, Perez CA, Brady LW. Perez and Brady's Principles and Practice of Radiation Oncology. 6th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.
11. Hossain S, Xia P, Chuang C, Verhey L, et al. Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys. 2008; 35: 4041-4048.
12. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology. 2005; 66(5 Suppl.): 83-94.
13. Drouin SJ, Vaessen C, Hupertan V, et al. Comparison of mid-term carcinologic control obtained after open, laparoscopic, and robotassisted radical prostatectomy for localized prostate cancer. World J Urol. 2009; 27: 599-605.
14. Amling CL, Blute ML, Bergstralh EJ, et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000; 164: 101-105.
15. Kuban DA, Thames HD, Levy LB, et al. Long-term multiinstitutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003; 57: 915-928.
16. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or '72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 25-33.
17. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013; 109: 217-221.
18. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014; 4: 240.
19. Bolzicco G, Favretto MS, Scremin E, et al. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat. 2010; 9: 473-477.
20. Sack GH. Comprehensive outpatient health assessment: a casefinding tool in 500 consecutive asymptomatic individuals. Medicine. 2009; 88: 268-278.
21. Joo JH, Kim YJ, Kim YS, et al. Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report. Radiat Oncol J. 2013; 31: 199-205.
22. Jung KW, Won YJ, Kong HJ, et al. Survival of Korean adult cancer patients by stage at diagnosis, 2006-2010: national cancer registry study. Cancer Res Treat. 2013; 45: 162-171.